Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 6, 2002, Pages 473-478

  Crul, Mirjam ^a,c   Beerepoot, Laurens V ^b   Stokvis, Ellen ^a   Vermaat, Johannes S P ^b   Rosing, Hilde ^a   Beijnen, Jos H ^a,c,d   Voest, Emile E ^b   Schellens, Jan H M ^c,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

ABT 518; Matrix metalloproteinases

Indexed keywords

ABT 518; BASIC FIBROBLAST GROWTH FACTOR; DRUG METABOLITE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HALF LIFE TIME; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SOLID TUMOR;

ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; FORMAMIDES; HALF-LIFE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MASS SPECTROMETRY; MATRIX METALLOPROTEINASES; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036453583     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0515-6     Document Type: Article

References (15)

1. Albert DH, Morgan DW, Magoc T, Tapang G, Kherzai A, Marcotte P, Elmore I, Glaser K, Pease L, Li J, Leal J, Michaelides M, Curtin M, Holms J, Wada C, Dai Y, Davidson SK (2000) Preclinical pharmacology of ABT-518, a novel and potent inhibitor of gelatinase A and B with anti-tumor activity. NCI-EORTC-AACR 11:301 (abs)
2. Bernhard EJ, Gruber SB, Muschel RJ (1994) Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 91:4293
3. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 19:3447
4. Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinase: Evolution, structure and function. Biochim Biophys Acta 1477:267
5. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387
6. Crawford HC, Matrisian LM (1996) Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 49:20
7. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N (2000) Metalloproteinases: Role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2:252
8. Duivenvoorden WCM, Hirte HW, Singh G (2001) Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY-129566 phase I study. Int J Cancer 91:857
9. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA (2000) Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 97:3884
10. Kanayama H (2001) Matrix metalloproteinases and bladder cancer. J Med Invest 48:31
11. Poon RTP, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19:1207
12. Ray JM, Stettler-Stevenson WG (1995) Gelatinase A activity directly modulated melanoma cell adhesion and spreading. EMBO J 14:908
13. Stokvis E, Rosing H, Crul M, Rieser MJ, Schellens JHM, Beijnen JH (2002) Quantitative analysis of the novel anticancer drug ABT-518 and six potential metabolites in human plasma using high-performance liquid chromatography coupled with turbo-ionspray tandem mass spectrometry. Proceedings of the 19th (Montreux) LC/MS Symposium, International Association of Environmental Analytical Chemistry. http://www.ia-eac.ch/lcmsbegin.htm
14. Vu TH, Werb Z (2000) Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev 14:2123
15. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ (1998) Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 16:2150